Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China

Ipsen

Status: Completed

Conditions: Acromegaly

Study type: Observational

Funder types: Industry

Identifiers

NCT05431803

CLIN-52030-455

Details and patient eligibility

About

This study aims to assess the one-year effectiveness and safety of LAN among patients with acromegaly in China in routine clinical practice. In addition, the study is designed to understand the real-world treatment patterns and outcomes of LAN among Chinese patients with acromegaly.

Enrollment: 129 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants who are able to comply with the protocol
• Participants with serum IGF-1 level above the ULN for age and sex, and serum fasting GH level above 2.5 μg/L
• Participants with acromegaly who are naïve to LAN treatment and about to initiate LAN

Exclusion criteria

• Participants who are currently participating in any investigational study or clinical trial of acromegaly
• Pregnant participants
• Participants with hypersensitivity to somatostatin or related peptides or to any of the excipients